The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease
Abstract
To gain a better understanding of the significance of α‐synuclein pathological conditions during disease progression in Parkinson's disease, we investigated whether 1) nigral neuronal loss in incidental Lewy body disease and Parkinson's disease donors is associated with the local burden α‐synuclein pathological conditions during progression of pathological conditions; 2) the burden and distribution of α‐synuclein pathological conditions are related to clinical measures of disease progression. Post‐mortem tissue and medical records of 24 Parkinson's disease patients, 20 incidental Lewy body disease donors, and 12 age‐matched controls were obtained from the Netherlands Brain Bank for morphometric analysis. We observed a 20% decrease in nigral neuronal cell density in incidental Lewy body disease compared with controls. Nigral neuronal loss (12%) was already observed before the appearance α‐synuclein aggregates. The progression from Braak α‐synuclein stage 3 to 4 was associated with a significant decline in neuronal cell density (46%). Nigral neuronal loss increased with later Braak α‐synuclein stages but did not vary across consecutive Braak α‐synuclein stages. We observed a negative correlation between neuronal density and local α‐synuclein burden in the substantia nigra of Parkinson's disease patients (ρ = −0.54), but no relationship with Hoehn & Yahr stage or disease duration. In conclusion, our findings cast doubt on the pathogenic role of α‐synuclein aggregates in elderly, but do suggest that the severity of neurodegeneration and local burden of α‐synuclein pathological conditions are closely coupled during disease progression in Parkinson's disease. © 2014 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Alafuzoff, I., Arzberger, T., Al‐Sarraj, S., Bodi, I., Bogdanovic, N., Braak, H., Bugiani, O., Del‐Tredici, K., Ferrer, I., Gelpi, E., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00147.x · Cited by 467
Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium
Alafuzoff, I., Thal, D. R., Arzberger, T., Bogdanovic, N., Al-Sarraj, S., Bodi, I., Boluda, S., Bugiani, O., Duyckaerts, C., Gelpi, E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0485-4 · Cited by 193
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Genetics and Pathogenesis of Parkinson's Syndrome
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-034145 · Cited by 416
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases
Chi, H., Chang, H.-Y., & Sang, T.-K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103082 · Cited by 412
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Majbour, N. K., Vaikath, N. N., van Dijk, K. D., Ardah, M. T., Varghese, S., Vesterager, L. B., Montezinho, L. P., Poole, S., Safieh-Garabedian, B., Tokuda, T., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0072-9 · Cited by 277
Self-citationMotor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Gut–brain axis and the spread of α‐synuclein pathology: Vagal highway or dead end?
Breen, D. P., Halliday, G. M., & Lang, A. E. (2019) · Movement Disorders · doi:10.1002/mds.27556 · Cited by 193
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Dijkstra, A. A., Ingrassia, A., de Menezes, R. X., van Kesteren, R. E., Rozemuller, A. J. M., Heutink, P., & van de Berg, W. D. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128651 · Cited by 167
Self-citationIn vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers
Dzamko, N., Rowe, D. B., & Halliday, G. M. (2016) · Movement Disorders · doi:10.1002/mds.26529 · Cited by 98
Garcia, P., Jürgens‐Wemheuer, W., Uriarte Huarte, O., Michelucci, A., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2022) · Glia · doi:10.1002/glia.24149 · Cited by 65
Acuña, L., Hamadat, S., Corbalán, N. S., González-Lizárraga, F., dos-Santos-Pereira, M., Rocca, J., Sepúlveda Díaz, J., Del-Bel, E., Papy-García, D., Chehín, R. N., et al. (2019) · Cells · doi:10.3390/cells8080776 · Cited by 62
Pan, Z., Niu, Y., Liang, Y., Zhang, X., & Dong, M. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9631-7 · Cited by 21
Metadata
- Authors
- Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Bank, N. B., Rozemuller, A. J. M., & van de Berg, W. D. J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-07-03
- Volume
- 29
- Issue
- 10
- Pages
- 1244-1251
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1943919857
- Cited by
- 176
- References
- 8
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.